Background: The neutrophil/lymphocyte ratio (NLR) has been reported to reflect systemic inflammation and independent prognostic significance in different types of cancer. In present study, we analyzed the association between NLR and clinicopathologic features and verified the significance of NLR as a prognostic factor for patients with breast cancer. Patients and Methods: A total of 388 patients with stage I -III breast cancer were retrospectively recruited into this study. Associations with clinicopathologic factors and NLR were assessed; disease-free survival and overall survival were estimated. Results: There was no significant association between NLR and clinicopathologic factors. Patients with low pre/post-treatment NLR had longer OS. Conclusion: A high pre/postoperative NLR may be considered an important factor for predicting poor prognosis in non-metastatic breast cancer patients.
Journal of Cancer Therapy tients were followed up by physical examination every 3 months, ultrasonography every 6 months, and computed tomography and bone scintigraphy annually.
Patients who had inflammatory, metastatic, or pregnancy-related breast cancer'; Patients with systemic inflammatory diseases, such as systemic lupus erythematosus, and rheumatoid arthritis; Patients with chronic diseases (liver cirrhosis, or end-stage renal disease) all were excluded.
Pre-treatment and post-treatment peripheral blood based parameters (total WBC count, ALC, ANC, hemoglobin level, and platelets count), were collected.
For pre-treatment peripheral blood parameters, blood samples were collected at the time of diagnosis before neoadjuvant chemotherapy or surgery. NLR was calculated by dividing ANC by ALC. For post-treatment peripheral blood parameters, blood samples were collected 3 weeks after surgery. Receiver operating curve (ROC) analysis was performed to select the most appropriate cutoff values for pre-and post-treatment NLR in order to stratify patients at a high risk of cancer recurrence or death.
Result
This study was conducted retrospectively on (388) patients with breast cancer from January 2009 to December 2015. Patients' characteristics at diagnosis are shown in Table 1 . As regarding pre-treatment hematological data, the mean absolute neutrophil count (ANC) was 4.18 ± 0.1 × 109 cells/L, mean absolute lymphocyte count (ALC) was 2.25 ± 0.04 × 109 cells/L, and mean NLR was 2.09 ± 0.7. Post-treatment hematological data, the mean ANC was 3.67 ± 0.1 × 109 cells/L, mean ALC was 1.91 ± 0.04 × 109 cells/L, mean NLR was 2.21 ± 0.1. As shown in Table 2 .
No significant change NLR ration related to age. • ILC 18 (4.6%)
• Mixed 14 (3.6%)
• DCIS 2 (0.5%)
• Others 3 (1.1%)
Histological Grade:
• Grade I 5 (1.4%)
• Grade II 344 (88.6%)
• • ER PR Positive 201 (51.8%)
• ER Positive PR Negative 49 (12.6%)
• ER Negative PR Positive 11 (2.9%)
• ER PR Negative 127 (32.7%)
• Triple Negative 28 (7.2%) HER2-neu expression:
• 0/+1 110 (28.4%)
• +2 20 (4.9%)
• +3 38 (9.8%)
• Unknown 221 (56.9%) 
Diagnostic Performance of Pre-Treatment and Post-Treatment NLR in Survival Prediction
It was noticed that at cutoff point ≤ 2.57, pretreatment NLR had 81% sensitivity and 33% specificity for prediction of survival in all studied patients with area under the curve was 0.54 and P value was 0.01 (Table 3 ). It was noticed that at cutoff point ≤ 2.27, post-treatment NLR had 71% sensitivity and 48% specificity for prediction of survival in all studied patients with area under the curve was 0.59 and P value was <0.001 (Table 3) . 
Characteristics of the Patients Based on Cutoff Point of Pre-Treatment NLR
Of the total patients (388), 316 patients had pre-treatment NLR less than 2.57
and 72 patients had pre-treatment NLR more than 2.57. As shown in Table 4 , based on cutoff point of pre-treatment NLR; it was noticed that there were no statistical significant differences between those patients with pre-treatment NLR < 2.57 and those with pre-treatment NLR ≥ 2.57 as regarding demographic data, baseline laboratory data, tumor characteristics, adjuvant radiotherapy and chemotherapy.
Outcome of Studied Patients Based on Cutoff Point of Pre-Treatment NLR
Frequency of relapse was higher in patients with pre-treatment NLR ≥ 2.57 range (47 -60 months). The median DFS time was 54 months. Neutrophil to lymphocyte ratio (NLR) has been analyzed in connection with several types of cancer including lung cancer [15] , gastric cancer [16] , colorectal cancer [17] , pancreatic cancer [18] , hepatocellular carcinoma [8] , ovarian cancer [19] , and some hematological malignancies [20] . And low NLR ratios have been associated with high DFS, OS and a better prognosis in many different cancer patients [21] .
In this study, we analyzed a cohort of 388 patients with non-metastatic breast cancer to demonstrate that the NLR could predict prognosis in these patients.
For patients in our study, the cutoff value of pretreatment NLR was 2.57. Most studies that evaluated NLR in breast cancer detected NLR with the range of (1.9 -4.0) [22] .
In the present study, we evaluated the relationship between pretreatment NLR, DFS, and OS for with non-metastatic breast cancer patients. We found that high pretreatment NLR is associated with increase rate of relapse ( Here, in present study, we evaluated the cutoff for post-treatment NLR in the studied patients. There was statistical significance between both groups and OS 
Conclusion
NLR is a simple marker of sub-clinical inflammation that can be easily assessed using white blood cell counting. Interestingly, a high pre/postoperative NLR may be considered an important factor for predicting poor prognosis in non-metastatic breast cancer patients. We need multicenter study to avoid heterogenicity.
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